Home » Business News » 2012 » November » November 30, 2012

Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family

November 30, 2012 - London


Orion Corporation is developing a budesonide-formoterol formulation combining budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator to expand the range of the inhalable Easyhaler® drug product family for treatment of asthma and COPD.

Based on the favorable pharmacokinetic study results of this Easyhaler-development programme Orion is planning to apply for a marketing authorisation for the combined budesonide-formoterol formulation. Orion currently estimates that the marketing authorisation application would be submitted in Europe during the first half of 2013.

Orion Corporation

Timo Lappalainen
President and CEO
Olli Huotari 
SVP, Corporate Functions

Contact persons:

Reijo Salonen, Senior Vice President, Research and Development (as ofMonday 3December)
tel. +358 50 966 3647

Jari Karlson, CFO
tel. +358 50 966 2883

Orion Corporation
Orionintie 1A, FI-02200 Espoo


Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Orion Oyj via Thomson Reuters ONE



Comment on this story